alexion pharmaceuticals, inc
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and … Alexion Pharmaceuticals, Inc. | 187,545 followers on LinkedIn. Eighteen analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. View the latest Alexion Pharmaceuticals Inc. (ALXN) stock price, news, historical charts, analyst ratings and financial information from WSJ. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (as fotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. Moors & Cabot Inc. lifted its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 28.6% in the 4th quarter, HoldingsChannel reports. The Company is focused on the development and commercialization of therapeutic products. Alexion Pharmaceuticals develops drugs that inhibit immune system functions that cause rare hematology, nephrology, neurology, metabolic disorders and cardiology. Alexion Pharmaceuticals, Inc. uses your network username and password to login to Box. The company was founded in 1992 and is headquartered in Boston, Massachusetts. Narrow-moat Alexion Pharmaceuticals reported fourth-quarter and full-year results that modestly beat our top line expectations. Alexion has acquired the companies: Alexion, Portola Pharmaceuticals, Strensiq, Syntimmune Inc What is Alexion's tech stack? The institutional investor owned 3,214 shares of the biopharmaceutical company’s stock after acquiring an additional 714 shares during the period. Rare inspiration. Alexion Pharmaceuticals, Inc. is a company in the U.S. stock market and it is a holding in 204 U.S.-traded ETFs. Alexion Pharmaceuticals, Inc. Corporate Headquarters: 100 College Street New Haven, Connecticut 06510 This investigation is: Open Latest Disclosure Date: February 4, 2020 Date of Original Disclosure: May 22, 2015 Agencies involved: U.S. Department of … Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). The Securities and Exchange Commission today announced that Boston-based pharmaceutical company Alexion Pharmaceuticals Inc. has agreed to pay more than $21 million to resolve charges that it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act (FCPA). Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has been assigned an average rating of "Hold" from the twenty-eight brokerages that are currently covering the company, MarketBeat Ratings reports. Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The technologies that are used by Alexion are: IBM SPSS, Adobe Illustrator, BlackBerry Enterprise Server, MATLAB Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) scored a price-to-earnings ratio above its average ratio, recording 56.65 x from its present earnings ratio. Get the latest Alexion Pharmaceuticals, Inc. ALXN detailed stock quotes, stock data, Real-Time ECN, charts, stats and … is investigating Alexion Pharmaceuticals, Inc. (“Alexion”) regarding possible breaches of fiduciary duties and other violations of law related to Alexion ’s agreement to be acquired by AstraZeneca PLC ("AstraZeneca").Under the terms of the agreement, Alexion' s shareholders will receive 2.1243 American Depository Shares of AstraZeneca and $60.00 in cash per share. Continue to login to Box through your network. Alexion Pharmaceuticals has 3,082 employees across 23 locations and $6.07 B in annual revenue in FY 2020. ALXN has around 20.9M shares in the U.S. ETF market. Changing lives. The company is also involved in immune system research related to autoimmune diseases. Shares of Alexion Pharmaceuticals Inc. ALXN slipped 1.31% to $155.51 Friday, on what proved to be an all-around mixed trading session for the stock market, with the … ALEXION PHARMACEUTICALS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Alexion Pharmaceuticals Inc. | 899527 | ALXN | US0153511094 About Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. See insights on Alexion Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Alexion Pharmaceuticals Inc. for $39 billion in cash and shares, adding a specialist in the treatment of rare diseases and immunology to its portfolio of medications for cancer and other illnesses. Alexion is a leading rare disease company with approximately 3,000 dedicated employees around the world serving patients in 50 countries. Rigrodsky Law, P.A. View Alexion Pharmaceuticals, Inc. ALXN investment & stock information. Find the latest news headlines from Alexion Pharmaceuticals, Inc. Common Stock (ALXN) at Nasdaq.com. The Company is focused on the development and commercialization of therapeutic products. Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its primary product, monoclonal antibody Soliris, treats two rare genetic blood disorders: paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Part of Alexion Pharmaceuticals, Inc.? Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. View today's stock price, news and analysis for Alexion Pharmaceuticals Inc. (ALXN). Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The Company is focused on the development and commercialization of therapeutic products. Plus, the 36-month beta value for ALXN is at 1.28. Moors & Cabot Inc.’s holdings in Alexion Pharmaceuticals were worth $502,000 at the […] Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. It employs around 2,400 people worldwide. Halper Sadeh LLP announces it is investigating whether the sale of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) to AstraZeneca PLC for $60.00 in cash and 2.1243 AstraZeneca American Depositary Shares for each Alexion share is fair to Alexion shareholders. Alexion Pharmaceuticals, Inc, Alexion 121 Seaport Blvd Boston Massachusetts United States - 02210 http://www.alexion.com Organization ID: 505957